Question 1

What is BROLUCIZUMAB used for?

Accepted Answer

BROLUCIZUMAB (brand name BEOVU) is a Other indicated for See full prescribing information.

Question 2

How does BROLUCIZUMAB work?

Accepted Answer

BROLUCIZUMAB works through the following mechanism: 12.1 Mechanism of Action Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110 , VEGF 121 , and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability..

Question 3

What are the most common side effects of BROLUCIZUMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for BROLUCIZUMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is BROLUCIZUMAB the same as BEOVU?

Accepted Answer

BEOVU is a brand name for BROLUCIZUMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

BROLUCIZUMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations